Tempus AI (NASDAQ:TEM) Earns Buy Rating from TD Cowen

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reissued by research analysts at TD Cowen in a report issued on Wednesday, Marketbeat.com reports. They presently have a $74.00 price target on the stock, up from their previous price target of $58.00. TD Cowen’s price objective indicates a potential upside of 13.86% from the stock’s previous close.

Several other research firms also recently commented on TEM. Piper Sandler restated a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Loop Capital dropped their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Trading Down 6.1 %

Shares of NASDAQ TEM opened at $64.99 on Wednesday. The business’s 50 day moving average is $44.36 and its two-hundred day moving average is $48.84. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI has a 52-week low of $22.89 and a 52-week high of $79.49.

Insider Activity

In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $62.50, for a total value of $1,250,000.00. Following the completion of the transaction, the chief operating officer now directly owns 962,442 shares of the company’s stock, valued at approximately $60,152,625. This trade represents a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,058,072 shares of company stock valued at $90,719,375.

Institutional Trading of Tempus AI

Several large investors have recently modified their holdings of the business. First Horizon Advisors Inc. acquired a new stake in Tempus AI during the third quarter worth approximately $30,000. FNY Investment Advisers LLC acquired a new stake in Tempus AI during the fourth quarter worth approximately $67,000. IFP Advisors Inc acquired a new stake in Tempus AI during the fourth quarter worth approximately $76,000. US Bancorp DE acquired a new stake in Tempus AI during the fourth quarter worth approximately $80,000. Finally, Vestor Capital LLC acquired a new stake in Tempus AI during the third quarter worth approximately $153,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.